Colin Zick is a Partner at Foley Hoag, where he co-chairs both the Health Care Compliance practice and the Privacy & Data Security practice. With over 30 years of experience navigating healthcare regulation and cybersecurity, Colin has seen administrations come and go—and knows that the fundamentals of compliance never change, even when everything else does.
Anne Herold Li is a Shareholder at Brownstein Hyatt Farber Schreck, where she serves as Managing Partner of the New York office and co-chairs the Life Sciences practice. A former epidemiologist who was once the “Rat Queen of New York City,” Anne pivoted to law after her brother suggested she might enjoy patent law—where someone pays you to learn the latest science every day.
In Today's Episode We Discuss:
- Supreme Court Tariff Ruling: What Does It Mean for 300,000+ Companies?
- The Court of International Trade Is About to Become Very Busy
- Bayh-Dole Act Enforcement: What's Old Is New Again
- Is Stronger Patent Control a Fix for NIH Funding Cuts?
- "Everything Everywhere All at Once" — Why There's No Single Thing to Focus On
- Control What You Can Control: The Bill Belichick Approach to Uncertainty
- The Biosecure Act Is Back: Five-Year Timeline, Immediate Impact
- How to Structure Deals in a Biosecure World
- Effective Lobbying: Implementation Is Everything
- Who Lives, Who Dies, Who Tells Your Story — The Hamilton Approach
- AI Regulation: US "Hold My Beer" vs. EU's "Let Me Give You a Tricycle"
- Why Crypto Wanted Regulation — And AI Will Too
- 50 State Regulation Is a Mess: The Train Track Problem
- The Great Molasses Flood: Why We Need AI Guardrails Now
- Should Patients Consent to AI in Their Treatment?
- Known Unknowns vs. Unknown Unknowns
- The Boring But Critical: Talk to Your Tax Advisor & Insurance Agent
- Force Majeure Clauses: The Lowest Boilerplate That Matters Most
- Why Europeans Strike Out "Act of God"
Need the life-sciences signal but short on time?
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
